News

  • 28 November 2011

    Sclerosis drug could slow eye cancer growth

    A drug used to treat amyotrophic lateral sclerosis, a form of motor neurone disease, has been shown to make eye tumours less likely to grow if they spread to other...

  • 27 November 2011

    Summit SMT C1100 secures FDA orphan drug status

    UK-based drug discovery company Summit has received the US Food & Drug Administration's (FDA) orphan drug status for SMT C1100, used to treat Duchenne muscular dystrophy.

Go Top